

## A

absent or reversed end-diastolic velocity	48:225
acrocentric rearrangements	48:389
adenomyoma	48:232
adenomyosis	48:232, 249
adnexal cyst	48:412
ADP-ribose pyrophosphatase	48:96
Alzheimer disease	48:273
amenorrhea	48:142
amniocentesis	48:389, 403
amnioinfusion	48:268
amyloid- $\beta$ peptide	48:273
androgen receptors	48:262
anemia	48:133
aneuploidy	48:159
antineoplastic drug resistance	48:239
apoptosis	48:28
appendix	48:412
autologous hemi-ovary	48:69

## B

bladder	48:38
bladder volume	48:258
blastocyst transfer	48:375
blood flow impedance	48:148
bone marrow	48:350

## C

calcium supplementation	48:124
calcium-vitamin D	48:142
cancer	48:239
cardiac tamponade	48:159
cardiovascular diseases	48:49
CD34	48:356
cellular schwannoma	48:176
cervical adenocarcinoma	48:370
cervical cancer	48:138
cervical intraepithelial neoplasia	48:254
cervix cancer	48:254
cesarean section	48:76
chromatin	48:28
chromosome 17p13.3 deletion	48:408
chromosome aberrations	48:292
COL4A2	48:3
computed tomography	48:163
congenital cystic adenomatoid malformation	48:278
congenital malformations	48:210, 218, 342
conization	48:254
copy number variation	48:89
cord blood	48:350
corpus luteum hemorrhage	48:108
craniorachischisis	48:286
Crinone 8% gel	48:375

## D

demographics	48:108
diastematomyelia	48:163
Doppler	48:268
Down syndrome	48:403
ductus venosus	48:268

## E

E7 oncogene	48:138
electroacupuncture	48:148
electrosurgery	48:254
embryo implantation	48:245
endometrial carcinoma	48:96
endometrium	48:96
endoscopy	48:282
Epstein-Barr virus	48:370
estradiol	48:60
estrogen	48:130
estrogen/progesterone therapy	48:60
exercise	48:49

## F

female students	48:124
fetal growth retardation	48:225
fetal heart rate	48:23
fetal monitoring	48:278
feticide	48:159
fibroid	48:335
follicle-stimulating hormone	48:72

## G

gastric cancer	48:282
genome-wide association studies	48:89
genotype	48:89
GnRH agonist	48:245
gonadotropin-releasing hormone agonist	48:133
granulosa cell tumor	48:72
group B streptococci	48:116
gynecologic surgery	48:120

## H

<i>Helicobacter</i>	48:282
hematopoietic stem cells	48:356
hemoperitoneum	48:108
HIV infection	48:65
homologous acrocentric rearrangement	48:403
hormone therapy	48:60
HPV-16	48:370
HPV-18	48:370
human papillomavirus	48:138
human placenta	48:28
hypercoiled cord	48:23
hysterectomy	48:254, 400

<b>I</b>			
i(21q)	48:403	N-methyl-D-aspartate receptors	48:273
<i>in vitro</i> fertilization	48:148	norethisterone	48:60
infertility	48:232	nuchal cord	48:23
inhibin A	48:72	Nudix	48:96
inhibin B	48:72	NUDT9	48:96
iniencephaly	48:286		
interferon regulatory factor-1	48:138	<b>O</b>	
suppressor protein		obstetric procedures	48:76
internal ribosome entry site	48:273	oligomenorrhea	48:142
intracytoplasmic sperm injection	48:245	omphalocele	48:286
intrauterine death	48:76	oocyte cryopreservation	48:15
isochromosome	48:403	operation time	48:400
		osteoblast	48:350
		ovarian cancer	48:9, 167
<b>K</b>		ovarian cystectomy	48:380
K <sub>2P</sub> channels	48:65		
KCNK channels	48:65	<b>P</b>	
kidney transplantation	48:249	pelvic mass	48:176
		perimenopause	48:133
<b>L</b>		perinatal mortality	48:225
laparoscopic	48:400	<i>periostin</i>	48:3
laparoscopically assisted vaginal	48:249	Pfannenstiel incision	48:120
hysterectomy		Pfannenstiel incision site	48:69
laparoscopy	48:9, 335, 380	phenotype	48:89
late termination	48:159	placenta	48:262
linkage disequilibrium	48:89	placenta previa	48:38
lissencephaly	48:408	placental abnormalities	48:3
<i>Listeria monocytogenes</i>	48:46	placental insufficiency	48:225
long-chain polyunsaturated	48:65	placentation	48:38
fatty acids		polycystic ovary syndrome	48:142
lower urinary tract symptoms	48:385	port site metastasis	48:9
luteal phase support	48:245	postmenopausal osteoporosis	48:350
luteal support	48:375	postmenopause	48:60
luteinizing hormone	48:72	preeclampsia	48:3, 113, 225, 262
		pregnancy	48:3, 46, 167, 282
<b>M</b>		pregnancy complications	48:225
magnetic resonance imaging	48:286, 408	pregnancy outcome	48:278
malignant melanoma	48:169	pregnancy rate	48:148
maternal screening	48:116	pregnant women	48:116
Maylard incision	48:120	premature menopause	48:69
meiotic spindle	48:15	premenstrual syndrome	48:124
memantine	48:273	prenatal diagnosis	48:163, 210, 218, 286, 292, 342
membrane transporters	48:239	preterm premature rupture	48:268
menopause	48:60	of membranes	
metastatic ovarian tumor	48:167	prevalence	48:385
metformin	48:142	pulsatility index	48:60
microarray-based comparative	48:152		
genomic hybridization		<b>Q</b>	
Miller-Dieker syndrome	48:408	quality indicator	48:400
mos45X/46X + mar	48:292		
mucocoele	48:412	<b>R</b>	
multidrug resistance	48:239	real-time polymerase chain reaction	48:116
mutation	48:130	receptor	48:130
myomectomy	48:335		
<b>N</b>			
neural tube defect	48:286		

recurrence	48:403	trophoblast	48:28
retroperitoneal	48:176	two-dimensional ultrasound	48:258
risk factors	48:49		
Robertsonian translocation	48:389		
robotic surgery	48:400		
<b>S</b>		<b>U</b>	
sex differentiation	48:292	24-hour urinary calcium	48:113
<i>sFlt1</i>	48:3	24-hour urinary protein	48:113
single ancillary trocar	48:380	ultrasonography	48:38
single nucleotide polymorphism markers	48:152	ultrasound	48:23, 163, 210, 218, 342, 408
single nucleotide polymorphisms	48:89	umbilical cord	48:23
spontaneous abortion	48:46	unexpected malignancies	48:9
stem cells	48:239	uniparental disomy	48:152, 389
subfertility	48:232	urinary frequency	48:385
suburethral slings	48:53	urinary stress incontinence	48:53
surgical blood loss	48:400	uterine artery ligation	48:249
surgical mesh	48:53	uterine artery	48:148
systems biology	48:356	uterine myoma	48:133, 176
		Utrogestan	48:375
<b>T</b>		<b>V</b>	
Taiwan	48:49	vagina	48:169
three-dimensional imaging	48:38	vaginal prolapse	48:53
three-dimensional ultrasound	48:258	velamentous cord insertion	48:23
transcription	48:28	ventriculomegaly	48:408
transmission	48:65	vitrification	48:15
transplantation	48:69, 356	vulva	48:169
transvaginal ultrasound	48:258		
trisomy 13	48:3, 210, 218, 342, 389	<b>W</b>	
		weak linkage	48:130
		weight loss	48:49